BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 30547205)

  • 1. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.
    Frydrychowicz A; Nagle SK; D'Souza SL; Vigen KK; Reeder SB
    J Magn Reson Imaging; 2011 Sep; 34(3):585-94. PubMed ID: 21751288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA.
    Vernuccio F; Bruno A; Costanzo V; Bartolotta TV; Vieni S; Midiri M; Salvaggio G; Brancatelli G
    Curr Probl Diagn Radiol; 2020; 49(6):398-403. PubMed ID: 31253462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
    Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
    Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
    Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
    Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
    Furlan A; Close ON; Borhani AA; Wu YH; Heller MT
    Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
    Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
    AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
    Lee EJ; Kim DJ; Cho ES; Kim KA
    J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function.
    Besa C; Bane O; Jajamovich G; Marchione J; Taouli B
    Magn Reson Imaging; 2015 Nov; 33(9):1075-1082. PubMed ID: 26119422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of contrast-enhanced portal vein imaging at the hepatobiliary phase obtained with gadobenate dimeglumine for predicting decompensation and transplant-free survival in chronic liver disease.
    Cai S; Lin N; Yang Y; Ma W; Wang Y; Lin X; Wang X; Zhao X
    Eur Radiol; 2023 May; 33(5):3425-3434. PubMed ID: 36897349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
    Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
    Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
    Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
    Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
    Vernuccio F; Cannella R; Gozzo C; Greco V; Midiri M; Furlan A; Tang A; Brancatelli G
    Abdom Radiol (NY); 2020 Aug; 45(8):2409-2417. PubMed ID: 32435849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
    Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
    Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.